Please cite this article in press Pavankumar Wankhade et al., Minamata Disease: A Review., Indo Am. J. P. Sci, 2024; 11 (08).

1. Kitamura S, Miyata C, Tomita M, et al. A central nervous system disease of unknown cause that occurred in the Minamata region: results of an epidemiological study. JEpidemiol. 2020;30(1):3-11. doi:10.2188/jea.JE20190173
2. WNYC. Mercury: how it made cats dance.
3. Kessler R. The Minamata Convention on Mercury: a first step toward protecting future generations. EnvironHealthPerspect. 2013;121(10):A304-A309. doi:10.1289/ehp.121-A304
4. Yorifuji T. Lessons from an early-stage epidemiological study of Minamata disease. JEpidemiol. 2020;30(1):12-14. doi:10.2188/jea.JE20190089
5. Yokoyama H. Mercury Pollution in Minamata. Singapore: Springer Singapore; 2018. doi:10.1007/978-981-10-7392-2
6. Japan, Ministry of the Environment. Lessons from Minamata disease and mercury management in Japan.
7. Matsumoto H, Koya G, Takeuchi T. FetalMinamata disease: A neuropathological study of two cases if intrauterine intoxication by methylmercury compound. J Neuropath Exper Neurol. 1965; 24:563–574.
8. Minamata Disease: Methylmercury Poisoning in Japan Caused by Environmental Pollution -(https://www.ncbi.nlm.nih.gov/pubmed/7734058)
9. Evaluation of Mercury Exposure Level, Clinical Diagnosis and Treatment for Mercury Intoxication -(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724159/)
10. https://pubmed.ncbi.nlm.nih.gov/9437807/
11. Nishimura H, Okamoto T.The Science of MinamataDisease(in Japanese). Tokyo: Nihon HyoronshaCo.,Ltd., 2001.
12. Takeuchi T, EtoK.The Pathology of MinamataDisease. A Tragic Story of Water Pollution(ed. collabo-ration by Nakayama H, Sumiyoshi A). Fukuoka:Kyushu University Press Inc., 1999.
13. Eto K, Yasutake A, Kuwana Tet al. Mercury poisoningin common marmosets – a study of selective vulner-ability within the cerebral cortex.Toxicol Pathol2001;5: 565–573.
14. Eto K, Yasutake Y, Korogi Yet al. Methylmercurypoisoning in common marmosets – MRI findings andperipheral nerve lesions.Toxicol Pathol2001;6: 723–734.
15. Hunter D, Russell DS. Focal cerebral and cerebellaratrophy in a human subject due to organic mercurycompounds.JNeurolNeurosurg Psychiatry1954;17:235–241.
16. Eto K. Pathology of Minamatadisease.Toxicol Pathol1997;6: 614–623.
17. Takeuchi T. Pathology of Minamata disease. In:Kutsuna M, ed.Minamata Disease. Kumamoto: Kuma-moto Shuhan Publishing Co, 1968; 141–256.
18. Eto K, Tokunaga H, NagashimaKet al. An autopsycase on Minamata disease (Methylmercury poisoning)– pathological viewpoints of peripheral nerves.ToxicolPathol2001;6: 714–722.
19. Takeuchi T, Eto N, Eto K. Neuropathology of child-hood cases of methylmercury poisoning (Minamatadisease) with prolonged symptoms, with particular ref-erence to the decortication syndrome.Neurotoxicology1979;1: 1–20.
20. EtoK,OyanagiS,Itai Yet al. A fetal type of Minamatadisease–An autopsy case report with special referenceto the nervous system.MolChem Neuropathol1992;16: 171–186.
21. ^ a b Official government figure as of March 2001. See “Minamata Disease: The History and Measures, ch2”
22. ^a b See “Minamata Disease Archives” Archived 2016-03-03 at the Wayback Machine, Frequently asked questions, Question 6
23. ^ See “Mercury poisoning of thousands confirmed” by Jonathan Watts, TheGuardian, 16 October 2001, retrieved 24 October 2006.
24. ^ Kawamura, Hiroki (2017). “The relation between law and technology in Japan: liability for technology-related mass damage in the cases of Minamata disease, asbestos, and the Fukushima Daiichi nuclear disaster”. ContemporaryJapan. 30 (1): 3–27. doi:10.1080/18692729.2018.1423459. S2CID159882741.
25. ^ See “Ten Things to Know about Minamata Disease” Archived2012-07-25 at the Wayback Machine by Soshisha – The Supporting Center for Minamata Disease
26. ^ Williams, C. (1998) Environmental Victims: New Risks new Injustice. London Earthscan.
27. ^”National Institute ForMinamata Disease”. Retrieved 11 October 2012.
28. ^”WHO Collaborating Centres Global database”. WorldHealthOrganisation. Retrieved 11 October 2012.
29. ^”Espacenet Patent search”. European Patent Office. Retrieved 11 October 2012.
30. ^a b Kapur, Nick (2018). Japan at the Crossroads: Conflict and Compromise after Anpo. Cambridge, Massachusetts: Harvard University Press. p. 272. ISBN 9780674988484.
31. ^”Environmental Protection Policy in Japan – Introduction”. Ministry of the Environment, Japan. Retrieved 13 October 2012.
32. Evaluation of Mercury Exposure Level, Clinical Diagnosis and Treatment for Mercury Intoxication -(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724159/)
33. https://www.kyouritsu-cl.com/en/explanation/patient.php
34. https://www.medicalnewstoday.com/articles/minamata-disease#Treatment
35. Investigation of the Cause of Minamata Disease -(http://nimd.env.go.jp/archives/english/tenji/b_corner/b03.html)
36. ^”Sur l’emploi de l’iodure de potassium pourcombattre les affections saturnines et mercurielles”, in Annalesdechimieetdephysique, t. 26, 3e série, 1849.
37. ^ “On the Employment of Iodide of Potassium as a Remedy for the Affections Caused by Lead and Mercury”, in BrForeignMedChirRev. 1853 Jan; 11(21): 201–224.
38. ^ a b c d e Clifton JC (April 2007). “Mercury exposure and public health”. PediatricClinicsofNorthAmerica. 54 (2): 237–69, viii. doi:10.1016/j.pcl.2007.02.005. PMID174489.
39. ^ Risher JF, Amler SN (August 2005). “Mercury exposure: evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning”. Neurotoxicology. 26 (4): 691–9. doi:10.1016/j.neuro.2005.05.004. PMID 16009427.
40. ^ a b Rooney JP (May 2007). “The role of thiols, dithiols, nutritional factors and interacting ligands in the toxicology of mercury”. Toxicology. 234 (3): 145–56. doi:10.1016/j.tox.2007.02.016. PMID 17408840.
41. Hazards of chelation therapy:Brown MJ, Willis T, Omalu B, Leiker R (August 2006). “Deathsresultingfromhypocalcemiaafteradministrationofedetatedisodium: 2003-2005”. Pediatrics. 118 (2): e534-6. doi:10.1542/peds.20060858. PMID 16882789. S2CID 28656831. Archived from the original on 2009-07-27.
42. Baxter AJ, Krenzelok EP (December 2008). “Pediatric fatality secondary to EDTA chelation”. Clinical Toxicology. 46 (10): 1083–4. doi:10.1080/15563650701261488. PMID 18949650. S2CID 24576683
43. Spiller HA (May 2018). “Rethinking mercury: the role of selenium in the pathophysiology of mercury toxicity”. ClinicalToxicology. 56 (5): 313–326. doi:10.1080/15563650.2017.1400555. PMC 4856720. PMID 29124976.